Evidence map›Paper›PMID 33871798›Full record

ArticleJournal of gastrointestinal cancer2022

Gastric and Small Intestine Gist: Results of 156 Cases in 20 Years.

S Lopez Gordo, C Bettonica, M Miró, F Estremiana, H Aranda, L Farran

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Surgical treatment of gastrointestinal stromal tumors.Journal of medicine and life · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

S Lopez GordoMaresme Health Consortium, Carr de Cirera 230, 08304, Mataró, Barcelona, Spain. slopezgord@csdm.cat.ORCID http://orcid.org/0000-0001-9558-0041
C BettonicaEsofagogastric Unit, Bellvitge University Hospital, de La Feixa Llarga, s/n L´Hospitalet de Llobregat, Barcelona, Spain.
M MiróEsofagogastric Unit, Bellvitge University Hospital, de La Feixa Llarga, s/n L´Hospitalet de Llobregat, Barcelona, Spain.
F EstremianaEsofagogastric Unit, Bellvitge University Hospital, de La Feixa Llarga, s/n L´Hospitalet de Llobregat, Barcelona, Spain.
H ArandaEsofagogastric Unit, Bellvitge University Hospital, de La Feixa Llarga, s/n L´Hospitalet de Llobregat, Barcelona, Spain.
L FarranEsofagogastric Unit, Bellvitge University Hospital, de La Feixa Llarga, s/n L´Hospitalet de Llobregat, Barcelona, Spain.
Bellvitge University Hospital · ESMaresme Health Consortium · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGastric and small intestine are the most common gastrointestinal stromal tumors (GISTs). There are few studies of patients who underwent surgical treatment with disparate findings. We aimed to evaluate the differences between groups and the risk factors for recurrence and mortality.

methodsA retrospective study of 96 gastric and 60 small intestine GIST was performed between 1995 and 2015. Both groups were compared in terms of clinicopathologic features, morbidity, recurrence, and mortality. Statistical analysis was performed with SPSS®.

resultsEighty-one gastric GISTs and 56 small intestine GISTs underwent surgical treatment. Gastrointestinal bleeding was the most common cause of emergency surgery being more frequent in gastric GIST (P = 0.009); however, emergency surgery was indicated more frequently in the small intestinal GIST (P = 0.004) and was mostly due to perforation (P = 0.009). With a median follow-up of 66.9 (39.7-94.8) months, 28 (20.4%) patients had recurrence. A mitotic index > 5 (P ≤ 0.001) and the intestinal location (P = 0.012) were significantly associated to recurrence. Tumor size > 15 cm (P = 0.001) and an age of ≥ 75 years (P = 0.014) were associated to mortality. On univariate analysis, higher mean values of Ki-67 were associated to higher mortality (P = 0.0032). Small intestine GIST presented lower disease-free survival (DFS) than that of gastric GIST (65.7% vs 90.8%) with P = 0.003. The overall survival (OS) of gastric and small intestine GIST was 74.7% and 71.6%, respectively (P = 0.68).

conclusionSmall intestine GIST received emergency surgery more frequently showing lower DFS and same OS than that of gastric GIST. We found that Ki-67 could be a prognostic factor. Further studies are necessary to assess whether Ki-67 is a prognostic risk factor for GISTs.

Indexed as

Gastrointestinal Stromal TumorsIntestinal NeoplasmsStomach NeoplasmsAgedHumansIntestine, SmallKi-67 AntigenPrognosisRetrospective StudiesKi-67 AntigenGastricGistIntestineRecurrence

Identifiers

PMID33871798
OpenAlexW3154873296

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.